PeptiVir is an early stage biopharmaceutical company
focused on the development and commercialization of a
conformationally-constrained, synthetic peptide-based vaccine platform for the
prevention of viral diseases.
PeptiVir’s lead product, PVI-1000, has the
potential to be a “universal” influenza vaccine wherein one or two
administrations could lead to sustained protection against multiple seasonal
and pandemic strains. This is in contrast to existing influenza vaccines that must
be generated and administered yearly and induce antibodies that provide
protection only against that year’s seasonal flu strains.
PVI-1000 is predicted to work by inducing
cross-reactive antibodies that would protect against multiple influenza virus